Edition:
India

AB Science SA (ABS.PA)

ABS.PA on Paris Stock Exchange

8.89EUR
7 Jul 2020
Change (% chg)

-- (--)
Prev Close
€8.89
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
224,478
52-wk High
€11.00
52-wk Low
€3.22

Latest Key Developments (Source: Significant Developments)

AB Science Authorized To Start Phase 3 Confirmatory Study Of Masitinib
Thursday, 24 Oct 2019 

Oct 24 (Reuters) - AB Science SA ::REG-AB SCIENCE GRANTED AUTHORIZATION TO INITIATE PHASE 3 CONFIRMATORY STUDY OF MASITINIB IN INDOLENT SYSTEMIC MASTOCYTOSIS.  Full Article

AB Science Provides Update On Masitinib Programs Timelines
Thursday, 10 Oct 2019 

Oct 10 (Reuters) - AB SCIENCE SA ::AB SCIENCE PROVIDES UPDATE ON MASITINIB PROGRAMS TIMELINES.COMPANY IS ON TRACK TO ANNOUNCE DATA IN SEVERE ASTHMA AND IN MS IN 4Q 2019.FINAL ANALYSIS OF SEVERE ASTHMA UNCONTROLLED WITH ORAL CORTICOSTEROIDS (STUDY AB07015) SEEN IN Q4 2019.FINAL ANALYSIS OF PROGRESSIVE PRIMARY AND SECONDARY MULTIPLE SCLEROSIS (STUDY AB07002) SEEN IN Q4 2019.FINAL ANALYSIS OF ALZHEIMER’S DISEASE (STUDY AB09004) SEEN IN Q4 2019/Q1 2020.FINAL ANALYSIS OF SEVERE ASTHMA UNCONTROLLED WITH INHALED CORTICOSTEROIDS (STUDY AB14001)SEEN IN Q2 2020.FINAL ANALYSIS OF PANCREATIC CANCER (STUDY AB12005) SEEN IN 2020.FINAL ANALYSIS OF METASTATIC PROSTATE CANCER (STUDY AB12003) SEEN IN 2020.  Full Article

AB Science Announces The Publication Of The Positive Phase 2/3 Clinical Trial With Masitinib
Monday, 8 Jul 2019 

July 8 (Reuters) - AB Science SA ::Reg-AB SCIENCE ANNOUNCES THE PUBLICATION OF THE POSITIVE PHASE 2/3 CLINICAL TRIAL WITH MASITINIB IN ALS IN THE JOURNAL AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION.STUDY AB10015 REACHED ITS PRIMARY ENDPOINT AND SHOWED THAT MASITINIB AT 4.5 MG/KG/DAY IN COMBINATION WITH RILUZOLE WAS ABLE TO SIGNIFICANTLY (P-VALUE < 0.05) SLOW ALSFRS-R DECLINE BY 27% AS COMPARED WITH THE ACTIVE RILUZOLE CONTROL AT WEEK 48.KEY SECONDARY ENDPOINT, PFS (A TIME-TO-EVENT ANALYSIS, MEASURING THE EARLIEST EVENT BETWEEN DEATH AND FUNCTIONAL DECLINE OF AT LEAST 9 POINTS IN ALSFRS-R)5, WAS ALSO STATISTICALLY SIGNIFICANT (P<0.05), WITH A CLINICALLY MEANINGFUL 25% DELAY IN PROGRESSION (MEDIAN PFS OF 20.0 MONTHS FOR MASITINIB AS COMPARED TO 16.0 MONTHS FOR CONTROL).OTHER SECONDARY ENDPOINTS WERE ALSO SIGNIFICANT (P<0.05), with a 29% SLOWING OF DETERIORATION IN QUALITY-OFLIFE (ALSAQ-40) AND A 22% SLOWING OF DETERIORATION IN RESPIRATORY FUNCTION (FVC).SAFETY WAS ACCEPTABLE AND CONSISTENT WITH MASITINIB’S KNOWN RISK PROFILE.  Full Article

AB Science Completes Reorganization Of Its Clinical Development Activity
Wednesday, 19 Dec 2018 

Dec 19 (Reuters) - AB SCIENCE SA ::REG-AB SCIENCE PROVIDES AN UPDATE ON THE RESTRUCTURING OF ITS CLINICAL DEVELOPMENT DEPARTMENT IN 2018.HAS COMPLETED REORGANIZATION OF ITS CLINICAL DEVELOPMENT ACTIVITY TO ENSURE COMPLIANCE WITH GOOD CLINICAL PRACTICES.ANSM INSPECTION WAS RECENTLY CONDUCTED TO ENSURE THAT CONDITIONS REQUIRED TO LIFT CLINICAL HOLD HAVE BEEN MET.AB SCIENCE WILL DISCLOSE AGENCY DECISION ONCE AVAILABLE.AT THIS STAGE, AB SCIENCE DOES NOT INTEND TO PROVIDE ANY INFORMATION REGARDING TIMING OF ANSM DECISION.  Full Article

AB Science Announces Masitinib Phase 3 Study In Alzheimer's Disease Completed Patient Recruitment
Monday, 22 Oct 2018 

Oct 22 (Reuters) - AB SCIENCE SA ::REG-AB SCIENCE ANNOUNCES THAT THE MASITINIB PHASE 3 STUDY IN ALZHEIMER'S DISEASE HAS COMPLETED PATIENT RECRUITMENT.FINAL RESULTS WILL BE AVAILABLE IN 2019.STUDY RECRUITMENT WAS COMPLETED WITH 721 ENROLLED PATIENTS.NEXT STEP FOR THIS STUDY IS A PRE-PLANNED INTERIM ANALYSIS, WHICH IS EXPECTED IN COMING MONTHS.  Full Article

AB Science H1 Net Loss 11.1 Million Euros
Monday, 1 Oct 2018 

Oct 1 (Reuters) - AB SCIENCE SA ::AB SCIENCE TODAY REPORTS ITS REVENUES FOR THE FIRST HALF OF 2018.NET LOSS OF 11.1MEUR IN FIRST HALF OF 2018.CASH POSITION OF 21.1 MEUR AS OF 30 JUNE 2018.AB SCIENCE IS EVALUATING POSSIBILITY TO RESUBMIT APPLICATION BASED ON FINAL RESULTS FROM STUDY AB10015.OPERATING LOSS AS AT 30 JUNE 2018 AMOUNTED TO 14,192 KEUR AS COMPARED WITH 13,709 KEUR AS AT 30 JUNE 2017.H1 REVENUE EUR 0.9 MILLION VERSUS EUR 0.8 MILLION YEAR AGO.AB SCIENCE INTENDS TO LAUNCH PHASE 1/2 STUDY IN REFRACTORY ACUTE MYELOID LEUKEMIA WITH NEW MOLECULE AB8939.  Full Article

-AB Science Reports Positive Idmc Recommendation To Continue Study Based On A Trend Analysis Of Study In Refractory Metastatic Colorectal Cancer
Monday, 23 Jul 2018 

July 23 (Reuters) - AB Science SA ::REG-AB SCIENCE REPORTS POSITIVE IDMC RECOMMENDATION TO CONTINUE THE STUDY BASED ON A TREND ANALYSIS OF THE MASITINIB PHASE 2/3 STUDY IN REFRACTORY METASTATIC COLORECTAL CANCER.STUDY'S PRIMARY ENDPOINT IS OVERALL SURVIVAL (OS).EXPECTS STUDY AB12010 TO BE COMPLETED IN 2019.SAYS A TREND ANALYSIS FOR OS WAS PLANNED AFTER A CERTAIN NUMBER OF EVENTS ARE OBSERVED.INTERIM ANALYSIS IS PLANNED AFTER AROUND 50% OF TOTAL NUMBER OF REQUIRED EVENTS.  Full Article

BRIEF-AB Science Postpones AGM To No Later Than September 30

* ANNOUNCES THE POSTPONEMENT OF ITS ANNUAL GENERAL SHAREHOLDERS’ MEETING